Full text
Earnings transcript
Read the complete earnings call transcript.
4151
4151.T
Kyowa Kirin Co., Ltd.
$2548.5
-11
(-0.43%)
| Exchange: | JPX |
| Market Cap: | 1.334T |
| Shares Outstanding: | 537.272M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Abdul Hafeez Mullick | |||||
| Full Time Employees: | 5669 | |||||
| Address: |
| |||||
| Website: | https://www.kyowakirin.com |
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company’s core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 442,233,000 | 495,558,000 | 496,826,000 |
| Gross Profit | 320,621,000 | 351,217,000 | 356,353,000 |
| EBITDA | 118,532,000 | 108,942,000 | 114,904,000 |
| Operating Income | 95,842,000 | 91,866,000 | 102,275,000 |
| Net Income | 81,188,000 | 59,870,000 | 67,040,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,025,942,000 | 1,067,363,000 | 1,107,860,000 |
| Total Liabilities | 189,523,000 | 216,552,000 | 214,528,000 |
| Total Stockholders Equity | 836,418,000 | 850,811,000 | 893,332,000 |
| Total Debt | 19,696,000 | 21,675,000 | 26,130,000 |
| Cash and Cash Equivalents | 403,083,000 | 244,681,000 | 218,769,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 115,551,000 | 67,884,000 | 96,619,000 |
| Capital Expenditure | -17,213,000 | -26,037,000 | -37,715,000 |
| Free Cash Flow | 98,338,000 | 41,847,000 | 58,904,000 |
| Net Income | 81,188,000 | 59,870,000 | 67,040,000 |
| Net Change in Cash | 63,889,000 | -158,402,000 | -25,912,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 565,572,219.055 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 594,693,902.105 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 579,269,500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 133,780,826.711 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 140,669,288.878 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 137,020,790.604 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 92,568,073.676 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 98,809,731.039 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 95,503,817.582 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 202,658,718.581 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 213,093,748.399 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 207,566,798.064 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 182.450 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 188.770 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 176.840 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 5 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 4 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about 4151.T valuation
Is Kyowa Kirin Co., Ltd. (4151.T) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Kyowa Kirin Co., Ltd. (4151.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is 4151.T a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4151.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is 4151.T’s P/E ratio?
You can see 4151.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for 4151.T?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is 4151.T a good long-term investment?
Whether 4151.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
4151.T
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.43
Trading Metrics:
| Open: | 2582 | Previous Close: | 2559.5 | |
| Day Low: | 2540 | Day High: | 2586 | |
| Year Low: | 2109 | Year High: | 2912 | |
| Price Avg 50: | 2404.84 | Price Avg 200: | 2464.4 | |
| Volume: | 1.678M | Average Volume: | 1.45M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free